Extended Data Fig. 9: PD-1 blockade potentiates anti-tumor immune response induced by PI3Kβ inhibition in PTEN-null mouse mammary tumors.
From: PI3Kβ controls immune evasion in PTEN-deficient breast tumours
a–b, Flow cytometry analysis of tumor cells and immune infiltrate from PP (a) or HER2/Neu+ (b) tumors harvested from FVB mice treated with AZD6482 or a vehicle control (n = 10 tumors per condition). c, H&E stain of representative tumor samples from mice (Exp. 1) treated with vehicle (n = 8) or combined AZD6482 and PD-1 blockade (αPD-1), including cases showing complete response (CR; n = 3) and delayed progressive disease (PD; n = 3). Scale bars = 100 μm. d–f, Flow cytometry analysis of tumor cells and immune infiltrate from PP tumor-bearing FVB mice treated with AZD6482 or αPD-1 as single agents or in combination (n = 10 tumors per group). Box plots represent median and inter-quartile range, and min-to-max error bars (whiskers). For comparison of two means (a–b), unpaired, two-tail t-test with Welch’s correction assuming unequal variance. For multiple comparisons (d–f), one-way ANOVA followed by Tukey’s multiple comparisons tests. g–h, RNA from bulk PP tumor fragments was analyzed by RNA-Seq (n = 6 per group). Results from GSEA compared to the vehicle control (g) and heatmap denoting expression of immune-related genes (h) are shown. Flow cytometry gating profiles available on Supplementary Figs. 5 and 6. MFI, mean fluorescence intensity; IFN, interferon; NES, normalized enrichment score; PRRs, pattern recognition receptors.
